108985
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
利用 HPV16 整合相关基因预测宫颈癌进展
Received 28 May 2025
Accepted for publication 26 September 2025
Published 22 October 2025 Volume 2025:17 Pages 3745—3760
DOI https://doi.org/10.2147/IJWH.S543345
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Matteo Frigerio
Yifan Yang,1 Chaoyang Sun,1 Hui Wang2,3
1Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China; 2Zhejiang Provincial Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases, Women’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China; 3Department of Gynecologic Oncology, Women’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China
Correspondence: Hui Wang, Department of Gynecologic Oncology, Women’s Hospital, Zhejiang University School of Medicine, Xueshi Road, Hangzhou, Zhejiang, 310000, People’s Republic of China, Email huit71@sohu.com
Purpose: Cervical cancer (CC) remains a significant global health burden among women, particularly in cases of advanced or recurrent disease. Current clinical parameters exhibit suboptimal accuracy in predicting disease progression. Given that HPV integration is a well-established oncogenic driver in cervical carcinogenesis, there is growing interest in leveraging HPV-related molecular signatures to improve risk stratification and guide personalized treatment strategies.
Patients and Methods: Our study design employed HPV16-postive samples from TCGA-CESC as the training set (n = 95) and a local cervical cancer cohort (n = 118) for independent validation. From differentially expressed genes (DEGs) identified in HPV16-integrated HaCaT cells, we developed a prognostic 9-gene signature through a rigorous two-stage selection process: feature reduction using LASSO regression along with 10-fold cross-validation, followed by stepwise Cox regression. The risk score’s predictive performance was systematically evaluated through Kaplan-Meier survival analysis, time-dependent ROC curves, ROC over time profiling, calibration plots, and nomogram construction. Mechanistic investigations included functional enrichment analysis, mutational profiling, and drug sensitivity prediction.
Results: The 9-gene signature (LCP1, CXCL11, NEK6, MCAM, PRRX2, NPL, PGLYRP3, SPRR3 and MMP1) demonstrated superior predictive accuracy compared to conventional clinical parameters. Mechanistic investigations revealed that the signature genes collectively influence tumor progression through two key pathways: modulation of tumor immune microenvironment and regulation of oncogenic mutation patterns. These findings were consistently supported by both functional enrichment analysis and comprehensive mutational profiling. Furthermore, pharmacological inhibition of NRF2 signaling may overcome cisplatin resistance in high-risk patients with NFE2L2-mutant tumors. While the signature shows significant clinical potential, further independent validation is required before it can be adopted into routine clinical practice.
Conclusion: We developed a robust nine-gene prognostic model for predicting Progression-Free Survival (PFS) in CC, which provides novel insights into HPV-associated oncogenesis and facilitates risk stratification and therapeutic decision-making in CC management.
Keywords: HPV16 integration, prediction model, cervical cancer, progression-free survival, risk stratification
1Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China; 2Zhejiang Provincial Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases, Women’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China; 3Department of Gynecologic Oncology, Women’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China
Correspondence: Hui Wang, Department of Gynecologic Oncology, Women’s Hospital, Zhejiang University School of Medicine, Xueshi Road, Hangzhou, Zhejiang, 310000, People’s Republic of China, Email huit71@sohu.com
Purpose: Cervical cancer (CC) remains a significant global health burden among women, particularly in cases of advanced or recurrent disease. Current clinical parameters exhibit suboptimal accuracy in predicting disease progression. Given that HPV integration is a well-established oncogenic driver in cervical carcinogenesis, there is growing interest in leveraging HPV-related molecular signatures to improve risk stratification and guide personalized treatment strategies.
Patients and Methods: Our study design employed HPV16-postive samples from TCGA-CESC as the training set (n = 95) and a local cervical cancer cohort (n = 118) for independent validation. From differentially expressed genes (DEGs) identified in HPV16-integrated HaCaT cells, we developed a prognostic 9-gene signature through a rigorous two-stage selection process: feature reduction using LASSO regression along with 10-fold cross-validation, followed by stepwise Cox regression. The risk score’s predictive performance was systematically evaluated through Kaplan-Meier survival analysis, time-dependent ROC curves, ROC over time profiling, calibration plots, and nomogram construction. Mechanistic investigations included functional enrichment analysis, mutational profiling, and drug sensitivity prediction.
Results: The 9-gene signature (LCP1, CXCL11, NEK6, MCAM, PRRX2, NPL, PGLYRP3, SPRR3 and MMP1) demonstrated superior predictive accuracy compared to conventional clinical parameters. Mechanistic investigations revealed that the signature genes collectively influence tumor progression through two key pathways: modulation of tumor immune microenvironment and regulation of oncogenic mutation patterns. These findings were consistently supported by both functional enrichment analysis and comprehensive mutational profiling. Furthermore, pharmacological inhibition of NRF2 signaling may overcome cisplatin resistance in high-risk patients with NFE2L2-mutant tumors. While the signature shows significant clinical potential, further independent validation is required before it can be adopted into routine clinical practice.
Conclusion: We developed a robust nine-gene prognostic model for predicting Progression-Free Survival (PFS) in CC, which provides novel insights into HPV-associated oncogenesis and facilitates risk stratification and therapeutic decision-making in CC management.
Keywords: HPV16 integration, prediction model, cervical cancer, progression-free survival, risk stratification